LogicBio Therapeutics (OTCMKTS:LOGC) Shares Gap Down – Should You Sell?

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) gapped down before the market opened on Friday. The stock had previously closed at $15.05, but opened at $14.55. LogicBio Therapeutics shares last traded at $14.55, with a volume of 683 shares.

LogicBio Therapeutics Stock Up 0.9%

The company has a market capitalization of $676.69 million, a PE ratio of -20.27 and a beta of 2.11. The stock’s fifty day moving average is $11.82 and its two-hundred day moving average is $9.80. The company has a current ratio of 1.87, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29.

LogicBio Therapeutics (OTCMKTS:LOGC) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10). The company had revenue of $33.60 million for the quarter, compared to analyst estimates of $33.60 million.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing treatments for rare and serious genetic diseases. The company’s research centered on technologies designed to modify or deliver genetic material directly inside the body.

LogicBio’s principal technology platforms included GeneRide, an in vivo gene-insertion approach intended to enable long-term expression of therapeutic genes, and GeneWare, a genome-editing platform. Its lead investigational program, LB-001, was developed as a potential treatment for methylmalonic acidemia, a rare inherited metabolic disorder.

Founded in 2014 and headquartered in Cambridge, Massachusetts, LogicBio operated primarily as a biotechnology research and development company serving the rare-disease and genetic-medicine markets.